The median age for those patients was 72.5 years (range 59–81), with 71.4% (20/28) undergoing 18F-DCFPyL PET/CT scan for evaluation of biochemical recurrence or PSA persistence after local therapy, 14.3% (4/28) for the initial staging of prostate cancer and 14.3% (4/28) for the evaluation of metastatic disease. The gene discussed is KLK3; the disease is prostate cancer.